No Detail Found!

Incidence of anti-tuberculosis drug induced liver injuries in patients receiving therapy at a Tertiary Care Hospital In Karachi: A cross-sectional study

Author(s)
Saad Najam Department of Pharmacology, Jinnah Medical and Dental College, Sohail University, Karachi, Pakistan
Samia Perwaiz Khan Department of Pharmacology, Department Biomedical and Biological Sciences, Jinnah Medical and Dental College, Karachi, Pakistan
Rizwana Warraich Department of Pharmacology, Department Biomedical and Biological Sciences, Jinnah Medical and Dental College, Karachi, Pakistan
Ajeet Kumar Department of Pharmacology, Medicare Hospital/Sohail Trust Hospital, Karachi, Pakistan
Nosheen Iqbal Department of Pharmacology, Medicare Hospital/Sohail Trust Hospital, Karachi, Pakistan
Syeda Urooj Department of Pharmacology, Medicare Hospital/Sohail Trust Hospital, Karachi, Pakistan
Abstract
Objective: To determine the prevalence and risk factors of anti-tuberculosis drug induced liver injury (AT-DILI) while assessing gender differences and documenting incidence trends. Methodology: We utilized a questionnaire survey, collection of sputum samples for acid-fast bacilli testing and liver function tests (LFTs). Results: Out 100 patients, 35 were males and 65 females. A total of 45 patients were tested positive for acid-fast bacilli (AFB) on smear. Most patients exhibited regular LFT results, signifying unremarkable hepatic function during TB therapy. However, among relapse and post-TB cases, abnormal LFT findings were often accompanied by jaundice. Conclusion: Among relapse and post-TB cases, abnormal LFT findings were often accompanied by jaundice. Further research is needed to elucidate mechanisms behind this increased vulnerability to prevent AT-DILI in populations.
Publication Details
Page(s) 493-496
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 49, Issue: 3, Year: 2024

Request the full text from PASTIC

Keywords
jaundice., abnormal liver function, drug-induced liver injury, DILI, Anti-tuberculosis drug therapy
References
Raviglione M,Sulis G .2016 .Tuberculosis 2015: Burden, Challenges and Strategy for Control and Elimination. Infect dis rep, 8 : 6570.
Ramappa V,Aithal GP .2013 .Hepatotoxicity Related to Antituberculosis Drugs: Mechanisms and Management. J clin exp hepatol, 3 : 37-49.
Bloom BR,Atun R,Cohen T,Dye C,Fraser H,Gomez GB,Holmes KK,Bertozzi S,Bloom BR,Jha P .2017 .The International Bank for Reconstruction and Development / The World Bank © 2017 International Bank for Reconstruction. Major Infectious Diseases, : .
Medscape . .Tuberculosis (TB) Treatment & Management. , : .
Li X,Tang J,Mao Y .2022 .Incidence and risk factors of druginduced liver injury. Liver Int, 42 : 1999-2014.
Li M,Luo Q,Tao Y,Sun X,Liu C .2021 .Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review. Front pharm, 12 : 806249.
Alqahtani S,Kashkary A,Asiri A,Kamal H,Binongo J,Castro K .2018 .Impact of mobile teams on tuberculosis treatment outcomes. Riyadh Region, Kingdom of Saudi Arabia, 7 : 29-33.
Chen X,Hu TY .2021 .Strategies for advanced personalized tuberculosis diagnosis: Current technologies and clinical approaches. Prec clin med, 4 : 35-44.
Heyckendorf J,Georghiou SB,Frahm N,Heinrich N,Kontsevaya I,Reimann M .2022 .. Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies. Clin microbiol rev, 35 : e0022721.
Cohen KA,Manson AL,Desjardins CA,Abeel T,Earl AM .2019 .Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges. Gen Med, 11 : 45.
Tweed CD,Wills GH,Crook AM,Dawson R,Diacon AH,Louw CE .2018 .Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC medicine, 16 : 46-9.
Kong X,Guo D,Liu S,Zhu Y,Yu C .2021 .Incidence, characteristics, and risk factors for drug‐induced liver injury in hospitalized patients: A matched case‐control study. Br J Clin Pharmacol, 87 : 4304-12.
Gaude GS,Chaudhury A,Hattiholi J .2015 .Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients. J fam med prim care, 4 : 238-43.
Bao Y,Ma X,Rasmussen TP,Zhong XB .2018 .Genetic Variations Associated with Anti-Tuberculosis DrugInduced Liver Injury. Curr pharmacol rep, 4 : 171-81.
Zhuang X,Li L,Liu T,Zhang R,Yang P,Wang X .2022 .Mechanisms of isoniazid and rifampicin-induced liver injury and the effects of natural medicinal ingredients: A review. Front pharmacol, 13 : 1037814.
Kim JH,Nam WS,Kim SJ,Kwon OK,Seung EJ,Jo JJ .2017 .Mechanism Investigation of Rifampicin-Induced Liver Injury Using Comparative Toxicoproteomics in Mice. Int j mol sci, 18 : .
Abid A,Subhani F,Kayani F,Awan S,Abid S. .2020 .Drug induced liver injury is associated with high mortality-A study from a tertiary care hospital in Pakistan. PloS one, 15 : e0231398.
Cavaco MJ,Alcobia C,Oliveiros B,Mesquita LA,Carvalho A,Matos F .2022 .Clinical and Genetic Risk Factors for Drug-Induced Liver Injury Associated with Anti-Tuberculosis Treatment-A Study from Patients of Portuguese Health Centers. J person med, : 12.
Devarbhavi H.,Drug-Induced Liver H. .2021 .. Clin liver dis, 18 : 108-10.
Moosa MS,Maartens G,Gunter H,Allie S,Chughlay MF,Setshedi M .2022 .Rechallenge after anti-tuberculosis druginduced liver injury in a high HIV prevalence cohort. Southern Afr j HIV med, 23 : 1376.
Clinton JW,Kiparizoska S,Aggarwal S,Woo S,Davis W,Lewis JH .2021 .Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. Drug safety, 44 : 1125-49.
Molla Y,Wubetu M,Dessie B .2021 .Anti-Tuberculosis Drug Induced Hepatotoxicity and Associated Factors among Tuberculosis Patients at Selected Hospitals, Ethiopia. Hepatic medicine. evid res, 13 : 1-8.
Saha A,Shanthi FXM,Winston AB,Das S,Kumar A,Michael JS .2016 .Prevalence of Hepatotoxicity from Antituberculosis Therapy: A Five-Year Experience from South India. J prim care commun health, 7 : 171-4.
0

Citations

0

Downloads

81

Views